PLEASANTON, Calif., July 29, 2026
10x Genomics has entered a multi-year research collaboration with Lausanne University Hospital (CHUV) to accelerate the development of next-generation cancer diagnostics using single cell and spatial biology technologies. The partnership aims to identify clinically actionable biomarkers capable of predicting treatment response across multiple cancer types, supporting more precise and personalized oncology care. Leveraging 10x Genomics’ Flex Apex, Xenium, and future Atera platforms, researchers will analyze tumor samples from patients with advanced cancers undergoing molecular tumor board evaluation. By integrating single cell sequencing, spatial transcriptomics, computational artificial intelligence, pathology, and clinical outcomes, the collaboration seeks to improve patient selection for targeted therapies, immunotherapies, and emerging precision medicines. The initiative further strengthens 10x Genomics’ commitment to expanding the clinical applications of advanced genomic technologies while helping transform the future of precision oncology and molecular diagnostics.
Collaboration Focuses on Biomarker Discovery for Precision Oncology
The strategic collaboration brings together the complementary strengths of 10x Genomics, a global leader in single cell and spatial biology technologies, and Lausanne University Hospital (CHUV), one of Switzerland’s leading academic medical centers recognized for excellence in precision medicine and translational cancer research. Through the multi-year study, investigators will evaluate hundreds of patients diagnosed with advanced solid tumors, including non-small cell lung cancer, breast cancer, bladder cancer, and melanoma. Using Flex Apex and Xenium platforms, with future expansion to the Atera platform, researchers will generate high-resolution molecular data from tumor tissues to identify biomarkers capable of predicting therapeutic response, disease progression, and patient prognosis. The collaboration reflects the growing need for more sophisticated diagnostic tools as oncology treatments become increasingly personalized through targeted therapies, antibody-drug conjugates, bispecific antibodies, and immune checkpoint inhibitors.
Single Cell and Spatial Technologies Expand Diagnostic Capabilities
A key objective of the collaboration is to demonstrate how single cell sequencing and spatial biology can provide significantly deeper biological insights than conventional diagnostic approaches. Unlike traditional bulk tissue analysis, these advanced technologies allow researchers to examine individual cells while preserving their spatial organization within the tumor microenvironment. By integrating single cell molecular profiles, spatial gene expression, computational AI, and clinical outcome data, investigators aim to better understand the biological mechanisms responsible for treatment response and therapeutic resistance. The study will also evaluate how these innovative technologies can complement existing standard-of-care diagnostic assays, with the long-term goal of incorporating newly discovered biomarkers into future clinical reporting frameworks and molecular tumor board decision-making. The research could significantly improve physicians’ ability to personalize cancer treatment based on each patient’s unique tumor biology.
Advertisement
Advancing the Future of Personalized Cancer Care
The collaboration represents another important step toward integrating advanced genomics technologies into routine clinical oncology practice. By creating a comprehensive multimodal dataset combining single cell, spatial biology, and clinical information, the project is expected to accelerate the discovery of biomarkers capable of guiding treatment selection across multiple cancer types. The initiative also highlights the growing convergence of genomics, artificial intelligence, digital pathology, and precision medicine, enabling researchers to develop increasingly accurate diagnostic tools for modern cancer care. As the number of targeted therapies and immunotherapies continues to expand, identifying patients most likely to benefit from specific treatments has become one of oncology’s greatest challenges. Through this collaboration, 10x Genomics and CHUV aim to generate the scientific evidence needed to support future diagnostic applications, ultimately improving treatment outcomes while advancing the next generation of precision oncology solutions.
Source: 10x Genomics press release
